Werner Meier - Concepedia

Author

Werner Meier

Also Known As

A. Meier, Werner, E.P.j.d Lauraine, Frederik Marmé, G. Scambia, H. J. Lück, Meier W., Meier, W A, Meier, Werner, Meier, Werner A., Peter Mallmann

412

Publications

11.4K

Citations

H-Index

107

Concepts

All Affiliations

Evangelisches Krankenhaus Düsseldorf Kliniken Essen-Mitte Ludwig-Maximilians-Universität München Charité - Universitätsmedizin Berlin Universität Hamburg

About

Werner Meier is an author at Evangelisches Krankenhaus Düsseldorf specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	55	5.6K
2	Health Sciences	6	6	580
3	Public Health	5	5	684
4	Arts	1	1	18
5	Blood Transplantation	1	1	25

Werner Meier

Publications

9.7K

Citations

H-Index

Page 1

	Year	Citations
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, New England Journal of Medicine	2012	1.9K
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, The Lancet Oncology Olaparib Maintenance TherapySerous Ovarian CancerMedicineCancer ManagementGynecology	2014	1.4K
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms Philipp Harter, Jalid Sehouli, Domenica Lorusso, New England Journal of Medicine	2019	571
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Andreas du Bois, Michael Quinn, Tate Thigpen, Annals of Oncology MedicineCancer ManagementReproductive HealthGynecologyGcig Occc 2004	2005	465
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, The Lancet Oncology Overall SurvivalMedicineMetronomic TherapyClinical TrialsGynecology	2016	444
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy Lars Hanker, Sibylle Loibl, Nicole Burchardi, Annals of Oncology MedicinePrimary Taxane/platinum-based TherapyGynecologyLine TherapyRelapsed Ovarian Cancer	2012	333
Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study Sven� Mahner, J Jueckstock, Felix Hilpert, JNCI Journal of the National Cancer Institute	2015	226
Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO Jacobus Pfisterer, B. Weber, Rainer Kimmig, JNCI Journal of the National Cancer Institute	2006	208
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial Andreas du Bois, Gunnar B. Kristensen, Isabelle Ray‐Coquard, The Lancet Oncology Placebo-controlled Phase 3MedicineMetronomic TherapyGynecologyStandard First-line Chemotherapy	2015	207
Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens Andreas du Bois, B. Weber, Justine Rochon, Journal of Clinical Oncology	2006	196

Page 1